<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17690">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876601</url>
  </required_header>
  <id_info>
    <org_study_id>LPS_DF Version 1.2</org_study_id>
    <nct_id>NCT02876601</nct_id>
  </id_info>
  <brief_title>Defibrotide in the Human Endotoxemia Model --‐ an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide</brief_title>
  <acronym>LPS_DF</acronym>
  <official_title>Defibrotide in the Human Endotoxemia Model -- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernd Jilma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Defibrotide is an anti-inflammatory and anti-coagulatory agent approved for treatment of
      veno-occlusive disease. Although it has been in clinical use for almost 30 years, the exact
      mechanism of action has never been fully elucidated. Thus, the effects of defibrotide will
      be investigated in the human endotoxemia model in order to gather further information on its
      actions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Defibrotide (DF) is a highly complex polydisperse mixture of single-stranded phosphodiester
      oligodeoxyribonucleotides derived from the controlled depolymerization of porcine intestinal
      mucosal DNA. The entire mode of action remains unknown. Its actions may be summarized to
      pro-fibrinolytic, anti-inflammatory and anti-coagulatory actions. To better define the
      mechanisms of Defibrotide the effects of the substance will be investigated in the
      well-established endotoxemia model. Sixteen healthy volunteers will be randomized to receive
      LPS±defibrotide/placebo and four subjects will be randomized to receive Placebo±
      defibrotide/placebo in a single center, randomized, double blind, placebo controlled,
      two-way crossover trial. Immediately after a 2h infusion of 6,25mg/kg bodyweight defibrotide
      or placebo a LPS bolus of 2ng/kg bodyweight will be infused. Analyses will be performed by
      blood sampling at pre-defined time-points.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in prothrombin fragments f1+2</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by elisa, the changes will be compared between the placebo and the verum phase within each subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in coagulation specific biomarkers</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Thrombin-Antithrombin Complexes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fibrinolytic biomarkers</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by elisa, D-Dimer, Plasmin-Antiplasmin Complexes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biomarkers</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>C-reactive Protein levels, Fibrinogen, TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in microparticle associated tissue factor activity</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by elisa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biomarkers of endothelial activation</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by elisa, von-willebrand-factor, E-selectin,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biomarkers of endothelial activation</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Circulatin Endothelial cells by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differential blood counts</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by flow cytometry, incl. platelet counts, absolute and relative counts of leucocytes, erythrocytes, and leucocyte subpopulations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure mmHg</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>safety parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature degrees centigrade</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>safety parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation in percent</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>safety parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate in beats per minute</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>safety parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Endotoxemia</condition>
  <arm_group>
    <arm_group_label>LPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defibrotide</intervention_name>
    <description>6.25mg/kg bodyweight over 2h infusion</description>
    <arm_group_label>LPS</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% sodium chloride)</intervention_name>
    <description>(0.9% sodium chloride) infusion over 2h infusion</description>
    <arm_group_label>LPS</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipopolysaccharide</intervention_name>
    <description>bolus infusion of 2ng/kg bodyweight lps</description>
    <arm_group_label>LPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years of age

          -  &lt;90kg body weight

          -  Normal findings in medical history and physical examination unless the investigator
             considers the abnormality to be clinically irrelevant

          -  Normal laboratory values unless the investigator considers abnormalities to be
             clinically irrelevant

          -  Ability to understand the purpose and nature of the study, as well as the associated
             risks

        Exclusion Criteria:

          -  Intake of any drugs that may interfere with the trial's endpoints or drugs (i.e.
             platelet inhibitors, anticoagulants, etc.)

          -  Positive results of HIV or hepatitis virology

          -  Acute illness with systemic inflammatory reactions

          -  Known allergies, hypersensitivities or intolerances to any of the used substances

          -  Acute or recent bleeding episodes, increased risk of bleeding at the discretion of
             the investigator

          -  Participation in an LPS trial within 6 weeks of the first study day

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Jilma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernd Jilma, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>29810</phone_ext>
    <email>bernd.jilma@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Schoergenhofer, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>29810</phone_ext>
    <email>christian.schoergenhofer@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Zeitlinger, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>29810</phone_ext>
      <email>markus.zeitlinger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Jilma, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>29810</phone_ext>
      <email>bernd.jilma@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Bernd Jilma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Schoergenhofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johann Bartko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Wohlfarth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Werner Rabitsch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georg Hopfinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>June 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Bernd Jilma</investigator_full_name>
    <investigator_title>Ao.Univ.Prof.Dr.med</investigator_title>
  </responsible_party>
  <keyword>Coagulation</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Defibrotide</keyword>
  <keyword>Fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be published in a peer-reviewed medical journal, individual data will not be presented or published, but may be made available by direct request to the PI (data may be made available in an anonymized fashion)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
